Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model

Vaccine

Volumn 30, Issue 8, 2012, Pages 1445-1452

  Goicochea, Marco A ^a   Zapata, Juan C ^a   Bryant, Joseph ^a   Davis, Harry ^a   Salvato, Maria S ^a   Lukashevich, Igor S ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Cell mediated immunity; Lassa virus; LCMV; Reassortant ML29; Vaccine development

Indexed keywords

GAMMA INTERFERON; LASSA VIRUS VACCINE; REASSORTANT ML29 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; INOCULATION; LASSA FEVER; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, VIRAL; ARENAVIRUSES, OLD WORLD; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; LASSA FEVER; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED CBA; REASSORTANT VIRUSES; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 84856567636     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.134     Document Type: Article

References (52)

1. McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr Top Microbiol Immunol 2002, 262:75-109.
2. Salvato M.S., Lukashevich I.S. Vaccines against Lassa fever. New generation vaccines 2009, Marcel Dekker, Inc., pp. 895-904. 4th edition. M.M. Levine (Ed.).
3. Moraz M.-L., Kunz S. Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev Anti-infect Ther 2011, 9(1):49-59. 2011/08/23.
4. Droniou-Bonzom M.E., Reignier T., Oldenburg J.E., Cox A.U., Exline C.M., Rathbun J.Y., et al. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J Virol 2011, October 5, 2011:JVI.05616-11.
5. Salvato M.S., Clegg J.C.S., Buchmeier M.J., Charrel R.N., Gonzalez J.P., Lukashevich I.S., et al. Arenaviridae. Virus taxonomy, IXth report of the ICTV 2005, 715-723. Elsevier/Academic Press, London. C.M. Fauquet, M.A. Mayo, J. Maniloff, U. Desselberger, L.A. Ball (Eds.).
6. Oldstone M. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr Top Microbiol Immunol 2002, 263:83-117.
7. Grant-Klein R., Altamura L.A., Schmaljohn C.S. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses. Antivir Res 2011, 162(1-2):148-161.
8. Khan S.H., Goba A., Chu M., Roth C., Healing T., Marx A., et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 2008, 78(1):103-115.
9. Fichet-Calvet E., Rogers D.J. Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 2009, 3(3). doi: e38810. 1371/journal. pntd. 0000388.
10. Loureiro M.E., Wilda M., Levingston Macleod J.M., D'Antuono A., Foscaldi S., Marino Buslje C., et al. Molecular determinants of Arenavirus Z protein homo-oligomerization and L polymerase binding. J Virol 2011, September 28, 2011:JVI. 05691-11.
11. Richmond J.K., Baglole D. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 2003, 327(November (7426)):1271-1275.
12. Paweska J., Sewlall N.H., Ksiazek T.G., Blumberg L.H., Hale M.J., Lipkin W.I. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 2009, 15:1598-1602.
13. Briese T., Paweska J.T., McMullan L.K., Hutchison S.K., Street C., Palacios G., et al. Genetic detection and characterization of lujo virus, a new hemorrhagic fever-associated arenavirus from Southern Africa. PLoS Pathog 2009, 4(5):e1000455.
14. Ishii A., Thomas Y., Moonga L., Nakamura I., Ohnuma A., Hang'ombe B., et al. Novel arenavirus Zambia. Emerg Infect Dis 2011, 17(10):1921-1924.
15. Cummins D., McCormick J., Bennett D., Samba J., Farrar B., Machin S., et al. Acute sensorineural deafness in Lassa fever. JAMA 1990, 264(16):2093-2096.
16. Liao B., Byl F.M., Adour K.K. Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause. Otolaryngol Head Neck Surg 1992, 106(3):226-229.
17. Macher A.B., Wolfe M.S. Historical Lassa fevers reports and 30-year clinical update. Emerg Infect Dis 2006, 12(5):835-837.
18. Neuman B.W., Bederka L.H., Stein D.A., Ting J.P.C., Moulton H.M., Buchmeier M.J. Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors. Antimicrob Agents Chemother 2011, 55(October (10)):4631-4638.
19. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287(18):2391-2405.
20. Cuevas C.D., Lavanya M., Wang E., Ross S.R. Junin virus infects mouse cells and induces innate immune responses. J Virol 2011, 85(November (21)):11058-11068.
21. Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T., Oro J.G.B. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 1987, 134:5-68.
22. Gowen B.B., Holbrook M.R. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antivir Res 2008, 78:79-90.
23. Lukashevich I.S., Vela E.M. Pathogenesis of Lassa virus infection in experimental animals. Molecular pathogenesis of hemorrhagic fever viruses 2010, 101-142. Transw Res Net, Kerala, India. E.M. Vela (Ed.).
24. Carrion R., Brasky K., Mansfield K., Johnson C., Gonzales M., Ticer A., et al. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol 2007, 81(April (12)):6482-6490.
25. Baize S., Marianneau P., Loth P., Reynard S., Journeaux A., Chevallier M., et al. Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J Virol 2009, 83(June (11)):5890-5903.
26. Sbrana E., Mateo R.I., Xiao S.-Y., Popov V.L., Newman P.C., Tesh R.B. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with pirital virus (arenaviridae): a rodent model of Lassa fever. Am J Trop Med Hyg 2006, 74(June (6)):1096-1102.
27. Zapata J.C., Pauza C.D., Djavani M.M., Rodas J.D., Moshkoff D., Bryant J., et al. Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Antivir Res 2011, 92(2):125-138.
28. Lukashevich I.S. Generation of reassortants between African arenaviruses. Virology 1992, 188(2):600-605.
29. Lukashevich I.S., Patterson J., Carrion R., Moshkoff D., Ticer A., Zapata J., et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 2005, 79(22):13934-13942.
30. Lukashevich I.S., Patterson J., Carrion R., Brasky K., Mansfield K., Zapata J., et al. Safety, immunogenicity, and efficacy of the ML29 vaccine for Lassa fever in small non-human primates. Vaccine 2008, 26:5246-5254.
31. Lukashevich I.S. A live reassortant vaccine for Lassa fever. Molecular pathogenesis of hemorrhagic fever viruses 2010, Transw Res Net, Kerala, India, pp. 143-70. E.M. Vela (Ed.).
32. Lukashevich I.S. Lassa virus lethality for inbred mice. Ann Soc Belg Med Trop 1985, 65(2):207-209.
33. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001, 75(December (23)):11677-11685.
34. Lukashevich I.S., Rodas J.D., Tikhonov I.I., Zapata J.C., Yang Y., Djavani M., et al. LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch Virol 2004, 149(12):2319-2336.
35. Lukashevich I.S., Clegg J.C., Sidibe K. Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J Med Virol 1993, 40(3):210-217.
36. Jiang X., Dalebout T.J., Bredenbeek P.J., Carrion R., Brasky K., Patterson J., et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 2011, 29(6):1248-1257.
37. Barber D.L., Wherry E.J., Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 2003, 171(July (1)):27-31.
38. La Posta V.J., Auperin D.D., Kamin-Lewis R., Cole G.A. Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J Virol 1993, 67(6):3497-3506.
39. Barkar N.D., Lukashevich I.S. Lassa and Mozambique viruses: cross protection in experiments on mice and action of immunosuppressants on experimental infections. Vopr Virusol 1989, 34:598-603.
40. McIntyre K.M., Bukovski J.F., Welsh R.M. Exquisite specificity of adoptive immunization in arenavirus-infected mice. Antivir Res 1985, 5:299-305.
41. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., et al. Lassa fever, effective therapy with ribavirin. N Engl J Med 1986, 314(1):20-26.
42. Botten J., Alexander J., Pasquetto V., Sidney J., Barrowman P., Ting J., et al. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 2006, 80(September (17)):8351-8361.
43. Boesen A., Sundar K., Coico R. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2. 1 Transgenic Mice. Clin Diagn Lab Immunol 2005, 12(October (10)):1223-1230.
44. Meulen J., Badusche M., Satoguina J., Strecker T., Lenz O., Loeliger C., et al. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 2004, 321(1):134-143.
45. Kotturi M.F., Swann J.A., Peters B., Arlehamn C.L., Sidney J., Kolla R.V., et al. Human CD8+ and CD4+ T cell memory to lymphocytic choriomeningitis virus infection. J Virol 2011, 85(November (22)):11770-11780.
46. Hastie K.M., Liu T., Li S., King L.B., Ngo N., Zandonatti M.A., et al. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proceedings of the National Academy of Sciences 2011, %R 101073/pnas1108515108.
47. Flatz L., Rieger T., Merkler D., Bergthaler A., Regen T., Schedensack M., et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathogen 2010, 6(3):e1000836.
48. Zhou S., Kurt-Jones E.A., Mandell L., Cerny A., Chan M., Golenbock D.T., et al. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur J Immunol 2005, 35(3):822-830.
49. Zhou S., Cerny A.M., Zacharia A., Fitzgerald K.A., Kurt-Jones E.A., Finberg R.W. Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus. J Virol 2010, 84(September (18)):9452-9462.
50. Zhou S., Kurt-Jones E.A., Cerny A.M., Chan M., Bronson R.T., Finberg R.W. MyD88 intrinsically regulates CD4 T-cell responses. J Virol 2009, 83(February (4)):1625-1634.
51. Jung A., Kato H., Kumagai Y., Kumar H., Kawai T., Takeuchi O., et al. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol 2008, 82(January (1)):196-206.
52. Zhou S., Halle A., Kurt-Jones E.A., Cerny A.M., Porpiglia E., Rogers M., et al. Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Mal-dependent inflammatory responses. J Neuroimmunol 2008, 194(1-2):70-82.